Objective: Germline pathogenic variants (PVs) are known to cause ~4% of prostate cancer, but other homologous repair genes, and Lynch syndrome genes are also involved. Our objective was to assess the contribution of germline and somatic gene variants to prostate cancer.

Methods And Analysis: We reviewed germline/tumour DNA testing from 450 localised or metastatic prostate cancer cases in NW England mainly from 2022 to 2024. ORs for additional genes used detection rates in controls from the BRIDGES study.

Results: 450 cases underwent germline/somatic testing with 2 germline PVs in (0.4%) and 27 in (6.0%)-total 6.4% and 6/328 (1.8%) in . There were 280 metastatic prostate cancer samples tested with 11 (4%) somatic and 7 (2.7%) somatic identified with 1 somatic . Total PVs in were 31/280 (11%), including germline and indeterminate. somatic PVs were found in 9/220 (4.1%), including 2 digenic with and 2 which were biallelic.

Conclusion: In this continuous clinical evaluation, is the most frequently identified prostate cancer gene with over 10% involvement in metastatic disease. and somatic PVs do not appear to be mutually exclusive. does not appear to be a significant contributor to prostate cancer progression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880781PMC
http://dx.doi.org/10.1136/bmjonc-2024-000592DOI Listing

Publication Analysis

Top Keywords

prostate cancer
24
metastatic prostate
8
somatic pvs
8
somatic
7
prostate
7
cancer
6
germline
5
pvs
5
uk-based clinical
4
clinical testing
4

Similar Publications

Positive surgical margins following radical prostatectomy significantly contribute to tumor recurrence. While systemic chemotherapy demonstrates limited efficacy in this context, local chemotherapy drug delivery systems based on nanomaterials offer promising strategies to address this issue by modifying drug release kinetics and distribution, thereby enhancing antitumor effects while minimizing the toxicities associated with systemic chemotherapy. In this study, we utilized electrospun nanofibrous mats loaded with docetaxel for sustained drug delivery.

View Article and Find Full Text PDF

Prostate cancer has garnered much importance in recent years due to its rising incidence and mortality among men worldwide. The ineffectiveness of existing therapies and adverse events associated with conventional treatment have led patients to turn towards traditional medicine for the management of prostate cancer. Cinnamomum zeylanicum bark essential oil (CZEO) possesses promising anticancer properties, yet the exact mechanism of action of CZEO for the management of prostate cancer remains unclear.

View Article and Find Full Text PDF

Cystopexy following anterior-approach robot-assisted radical prostatectomy enhances early continence recovery.

J Robot Surg

March 2025

Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333423, Taiwan.

To evaluate the effect of cystopexy on continence recovery after anterior-approach transperitoneal robot-assisted radical prostatectomy (RaRP). We retrospectively analyzed continence recovery of patients with prostate cancer receiving RaRP in a transperitoneal anterior-approach manner with or without cystopexy. Continence recovery is defined as complete intact continence without safety pad utility.

View Article and Find Full Text PDF

Purpose: To evaluate MRI and histological concordance in prostate cancer (PCa) identification via mapped transperineal biopsies.

Methodology: Retrospective per-lesion analysis of patients undergoing MRI and transperineal biopsy at the Valencian Institute of Oncology (2016-2024) using CAPROSIVO PCa data. Patients underwent MRI, with or without regions of interest (ROI), followed by transperineal biopsies (3-5 cores/ROI, 20-30 systematic).

View Article and Find Full Text PDF

Purpose: Despite the growing adoption of HIFU treatment for localized prostate cancer (PC), standardized criteria for evaluating success and predicting recurrence remain undefined. Herein, we analyze the predictive value of noninvasive tools such as PSA dynamics and MRI to determine recurrence.

Methods: We identified from our HIFU therapy prospective registry patients who developed biopsy-proven recurrence, between 2016 and 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!